@travelbug2 & @Eaglenebula thank you for your responses and it...

@travelbug2 & @Eaglenebula thank you for your responses and it has more than clarified my thoughts. I also thank anyone else that may offer any further contribution.

In layman's terms the practical side of the business and by that I mean the drug developments and trials (assuming positive results) will prove the technology works in producing drugs that are targeted at specific cells

Bring in the addition of the AI collaboration and to me ( I have much more expertise in technology than medical science) tells me that whilst we (the shareholders ) do not have 100% view on the technology part of the business, that collaboration would not have taken place if there was not a very serious prospect of it producing a successful outcome in respect to a technology that in itself will rapidly assist in the R&D of drugs

I also think that the icing on the cake to make AI collaboration happen was the PKD findings. I could be wrong we will see

Be careful everyone we could be on a serious winner here

DYOR and all that stuff